Market closed
IO Biotech/$IOBT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Ticker
$IOBT
Sector
Trading on
Industry
Biotechnology
Headquarters
Copenhagen, Denmark
Employees
78
Website
IO Biotech Metrics
BasicAdvanced
$56M
Market cap
-
P/E ratio
-$1.37
EPS
0.27
Beta
-
Dividend rate
Price and volume
Market cap
$56M
Beta
0.27
52-week high
$2.10
52-week low
$0.66
Average daily volume
569K
Financial strength
Current ratio
5.372
Quick ratio
4.994
Long term debt to equity
1.826
Total debt to equity
2.782
Management effectiveness
Return on assets (TTM)
-45.91%
Return on equity (TTM)
-78.50%
Valuation
Price to book
0.77
Price to tangible book (TTM)
0.77
Price to free cash flow (TTM)
-0.65
Growth
Earnings per share change (TTM)
-41.39%
3-year earnings per share growth (CAGR)
-83.69%
What the Analysts think about IO Biotech
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for IO Biotech stock.
IO Biotech Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IO Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IO Biotech News
AllArticlesVideos
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewsWire·1 month ago
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for IO Biotech stock?
IO Biotech (IOBT) has a market cap of $56M as of December 13, 2024.
What is the P/E ratio for IO Biotech stock?
The price to earnings (P/E) ratio for IO Biotech (IOBT) stock is 0 as of December 13, 2024.
Does IO Biotech stock pay dividends?
No, IO Biotech (IOBT) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next IO Biotech dividend payment date?
IO Biotech (IOBT) stock does not pay dividends to its shareholders.
What is the beta indicator for IO Biotech?
IO Biotech (IOBT) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.